Should you invest in Chimerix Inc (CMRX) stock? Here’s is what you need to know

Chimerix Inc is a biopharmaceutical organization, which participates in the exploration, advancement, and commercialization of drug items. The company operates in the industry of biotechnology and the operating sector of the firm is healthcare. The stock of Chimerix Inc trades under the ticker “CMRX”. The firm has a market capitalization of $436.89 million. Currently, the stock price of CMRX is $5.02 per unit. Moreover, CMRX has its headquarters in North Carolina.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Business Description

Chimerix is a biopharmaceutical organization whose mission is to foster meds that genuinely improve and broaden the existence of patients confronting lethal sicknesses. The FDA endorsed TEMBEXA (brincidofovir) for the therapy of smallpox as a clinical countermeasure.

Its two most progressive clinical-stage improvement programs are ONC201 and dociparstat sodium (DSTAT). ONC201 is being developed for repetitive H3 K27M-freak glioma as its lead sign. DSTAT is in Phase 3 advancement as a potential first-line treatment in the mix with standard chemotherapy for the treatment of intense myeloid leukemia (AML).

TEMBEXA is a lipid form that acts through the hindrance of viral DNA union that is a clinical countermeasure for smallpox. TEMBEXA possibly fills a significant job as a treatment countermeasure to smallpox. It has a separated system of activity, a somewhat high boundary to the opposition and accessible proof recommends it tends to be utilized in patients who have gotten the other FDA-supported smallpox antiviral treatment.


Chimerix last declared its quarterly income results in March. The biopharmaceutical organization detailed $0.45 EPS for the quarter. Chimerix had a negative net edge of 8,753.71% and a negative profit from a value of 84.90%. The business had an income of $0.05 million during the quarter, contrasted with expert assessments of $45.06 million. During a similar period, last year, the organization acquired $0.19 EPS. Investigators anticipate that Chimerix will post – 0.11 EPS for the ongoing year.

Various institutional financial backers and speculative stock investments have as of late traded portions of CMRX. Marshall Wace LLP obtained another situation in Chimerix during the first quarter worth about $166,000. Morgan Stanley expanded its property in Chimerix by 55.2% during the second quarter. Parametric Portfolio Associates LLC expanded its possessions in CMRX by 26.9% during the second quarter.

PAX Financial Group LLC bought another stake in Chimerix during the third quarter worth about $198,000. At long last, SG Americas Securities LLC bought another stake in Chimerix during the third quarter worth about $204,000. 63.38% of the stock is right now claimed by mutual funds and other institutional financial backers.

In March, CMRX announced that its CEO Mike Sherman and Chief Business Officer took part in two of the main gatherings including the fireside visit at the Cowen and Company 42nd Annual Health Care Conference, and the Maxim Group 2022 Virtual Growth Conference hung on March 7 and March 28-30 individually.


CMRX income is supposed to develop by 40.3% each year and it is exchanging at 95.3% underneath its fair worth evaluations. Thus, the financial backers ought to be judicious prior to putting resources into this stock, as the income is anticipated to develop by a normal of 76% in the following three years.

Related Posts